Theratechnologies submitted

Related by string. * : Theratechnologies TSX TH . Theratechnologies . Contacts Theratechnologies Inc. . Theratechnologies Announces / submitter . Submitting . submitting . SUBMITTED . Submitter . Submitted : - -ON SLAUGHTER DATA SUBMITTED . ON SLAUGHTER DATA SUBMITTED . submitted Biologics License . submitted Marketing Authorization . By Submitted Copy . Commentary submitted * *

Related by context. Frequent words. (Click for all words.) 52 Drug Application 52 FDA Approval 51 Marketing Authorization Application MAA 51 New Drug Application 51 Drug Application ANDA 50 sNDA 47 ANDAs 46 Complete Response Letter 46 Orphan Drug Designation 45 ANDA 45 Abbreviated New 43 PRX # 43 Priority Review 42 Satraplatin 42 PDUFA date 42 Phase IIa trial 42 APF# 42 NDA submission 42 investigational compound 42 intravenous formulation 41 Fast Track designation 41 approvable letter 41 Dyloject 41 IND enabling 41 NovaDel 40 cutaneous T cell 40 Phase 2b study 40 Phase 2a clinical 40 resubmission 40 Investigational 40 Pennsaid 40 Phase 2b trial 40 Sucampo 40 Act PDUFA 40 Phase Ib 39 orally administered 39 New Drug IND 39 Zenvia 39 Phase 1b 38 Marqibo 38 fidaxomicin 38 initiate Phase 38 clofarabine 38 linaclotide 38 Shionogi 38 Dacogen 38 Iluvien 38 RELISTOR 38 lubiprostone 38 INCB# [002] 37 Qutenza 37 CORLUX 37 FOSRENOL 37 pralatrexate 37 Phase IIa clinical 37 Phase IIb clinical 37 Phase 2a 37 Phase III clinical trials 37 satraplatin 36 ADVEXIN 36 Kuvan 36 EpiCept 36 Phase 2b 36 pivotal Phase III 36 BioMimetic 36 Ceplene 36 Clolar 36 & JPRD 36 VYVANSE 36 Riquent 36 Entereg 36 LEVADEX 36 IND 35 Special Protocol Assessment 35 Phase 2b clinical 35 CHMP 35 naproxcinod 35 KRYSTEXXA 35 Drug Administration FDA 35 Phase IIa 35 Phase IIb trial 35 Phase III clinical 35 orphan drug 35 Phase II 35 XIAFLEX 35 Phase IIb 34 investigational drug 34 Phase III 34 investigational 34 European Medicines Agency 34 indiplon 33 AzaSite 33 pivotal Phase 33 Phase III trials 32 Antegren 32 ceftobiprole 32 preclinical 32 BLA 31 Bronchitol 28 LibiGel 26 clinical trial

Back to home page